Galapagos ADR had its Relative Strength (RS) Rating upgraded from 66 to 77 Monday — a welcome improvement, but still below the 80 or higher score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks compares to other publicly traded companies.
Decades of market research shows that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Galapagos ADR can continue to rebound and clear that threshold.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a base and break out.
Galapagos ADR showed 0% EPS growth in the latest quarterly report. Sales gains came in at 20%.
The company holds the No. 58 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
